Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

J. M. Michot; L. Albiges; N. Chaput; V. Saada; F. Pommeret; F. Griscelli; C. Balleyguier; B. Besse; A. Marabelle; F. Netzer; M. Merad; C. Robert; F. Barlesi; B. Gachot; A. Stoclin

doi:10.1016/j.annonc.2020.03.300

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

J. M. Michot, L. Albiges, N. Chaput, V. Saada, F. Pommeret, F. Griscelli, C. Balleyguier, B. Besse, A. Marabelle, F. Netzer, M. Merad, C. Robert, F. Barlesi, B. Gachot, A. Stoclin

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

272 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	961-964
Nombre de pages	4
journal	Annals of Oncology
Volume	31
Numéro de publication	7
Les DOIs	https://doi.org/10.1016/j.annonc.2020.03.300
état	Publié - 1 juil. 2020

Accès au document

10.1016/j.annonc.2020.03.300

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Michot, J. M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., & Stoclin, A. (2020). Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Annals of Oncology, 31(7), 961-964. https://doi.org/10.1016/j.annonc.2020.03.300

@article{81bf3586fc754491b306eb2466ef53ef,

title = "Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report",

author = "Michot, {J. M.} and L. Albiges and N. Chaput and V. Saada and F. Pommeret and F. Griscelli and C. Balleyguier and B. Besse and A. Marabelle and F. Netzer and M. Merad and C. Robert and F. Barlesi and B. Gachot and A. Stoclin",

note = "Funding Information: None declared. JMM reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Agios, Amgen, Astex, AstraZeneca, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Forma, Genentech, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Oncopeptides AB, Roche, Sanofi, Taiho, and Xencor, outside the submitted work, and personal fees or travel grants or ad-board: Astex, Iqone, Mundipharma, and Bristol-Myers Squibb, outside the submitted work. BB reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals, outside the submitted work. CR reports personal fees for advisory boards from Bristol-Myers Squibb (BMS), Pierre Fabre, Novartis, Amgen, Merck, and Roche, outside the submitted work. FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. AM reports sponsored research at Gustave Roussy Cancer Center with: Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor, outside the submitted work.",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.annonc.2020.03.300",

language = "English",

volume = "31",

pages = "961--964",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "7",

}

Michot, JM, Albiges, L, Chaput, N, Saada, V, Pommeret, F, Griscelli, F, Balleyguier, C, Besse, B, Marabelle, A, Netzer, F, Merad, M, Robert, C, Barlesi, F, Gachot, B & Stoclin, A 2020, 'Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report', Annals of Oncology, VOL. 31, Numéro 7, p. 961-964. https://doi.org/10.1016/j.annonc.2020.03.300

TY - JOUR

T1 - Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure

T2 - a case report

AU - Michot, J. M.

AU - Albiges, L.

AU - Chaput, N.

AU - Saada, V.

AU - Pommeret, F.

AU - Griscelli, F.

AU - Balleyguier, C.

AU - Besse, B.

AU - Marabelle, A.

AU - Netzer, F.

AU - Merad, M.

AU - Robert, C.

AU - Barlesi, F.

AU - Gachot, B.

AU - Stoclin, A.

N1 - Funding Information: None declared. JMM reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Agios, Amgen, Astex, AstraZeneca, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Forma, Genentech, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Oncopeptides AB, Roche, Sanofi, Taiho, and Xencor, outside the submitted work, and personal fees or travel grants or ad-board: Astex, Iqone, Mundipharma, and Bristol-Myers Squibb, outside the submitted work. BB reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals, outside the submitted work. CR reports personal fees for advisory boards from Bristol-Myers Squibb (BMS), Pierre Fabre, Novartis, Amgen, Merck, and Roche, outside the submitted work. FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. AM reports sponsored research at Gustave Roussy Cancer Center with: Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor, outside the submitted work.

PY - 2020/7/1

Y1 - 2020/7/1

UR - http://www.scopus.com/inward/record.url?scp=85083292393&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.03.300

DO - 10.1016/j.annonc.2020.03.300

M3 - Letter

C2 - 32247642

AN - SCOPUS:85083292393

SN - 0923-7534

VL - 31

SP - 961

EP - 964

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -